Century Therapeutics (NASDAQ:IPSC) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Century Therapeutics (NASDAQ:IPSC) from a hold rating to a sell rating in a research report report published on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Century Therapeutics in a report on Saturday, September 27th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $3.75.

Century Therapeutics Price Performance

IPSC opened at $0.56 on Friday. The firm has a market capitalization of $47.97 million, a P/E ratio of -1.91 and a beta of 1.78. Century Therapeutics has a one year low of $0.34 and a one year high of $1.83. The company has a fifty day moving average price of $0.52 and a 200-day moving average price of $0.54.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.38). Century Therapeutics had a negative return on equity of 11.53% and a negative net margin of 19.10%. On average, analysts expect that Century Therapeutics will post -1.61 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Prudential Financial Inc. bought a new position in Century Therapeutics in the second quarter worth about $25,000. Qube Research & Technologies Ltd bought a new position in shares of Century Therapeutics in the 2nd quarter worth approximately $38,000. Jane Street Group LLC raised its position in shares of Century Therapeutics by 166.2% in the 4th quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock worth $49,000 after acquiring an additional 29,992 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Century Therapeutics in the 2nd quarter valued at approximately $50,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Century Therapeutics during the second quarter valued at approximately $51,000. 50.20% of the stock is owned by hedge funds and other institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.